Forward Pharma’s challenge to Biogen’s patent on its blockbuster multiple sclerosis medication Tecfidera has been officially thwarted.
This week, a U.S. federal appeals court upheld a March 2017 ruling protecting the patent, which will also keep Biogen from having to pay future royalties to Forward. The row over Tecfidera has centered around its active ingredient, dimethyl fumarate. Tecfidera, which is the best-selling oral medication for MS on the market, raked in about $4.2 billion in sales last year.
Forward said it is now “considering its options in response to the decision.” The company also appealed a failed patent challenge that is ongoing in the EU.
Read the full Reuters report.